Translation of "Orphan disease" in German

The prevalence of this disease thus falls well within the criteria for the grant of orphan (rare disease) status.

I'm in town for the Rare and Orphan Disease fundraiser, but I have a problem, Hank.

There is a small chance that we will get a genetic signature that is so strong for a particular orphan disease or patient population that it will make our own research contribution almost redundant.

His international experience provides him with a unique knowledge of different markets and drug-device combinations in orphan disease indications.

Dr. Karl Nägler, partner at Gimv, commented: "It is a great opportunity to invest in a company focusing on a life-threatening orphan disease with high unmet medical need.

This series includes a list of rare diseases, reports on epidemiological data, list of orphan drugs, rare disease registries in Europe, list of research infrastructures useful to rare diseases in Europe, Orphanet's annual activity report, and Orphanet's satisfaction surveys, as well as the list of experts having contributed to data in Orphanet.

This includes all the substances which have been granted an orphan designation for disease(s) considered as rare in Europe or the USA, whether they were further developed to become approved drugs with marketing authorisation (MA) or not.

The list of Orphan Drugs in the Orphanet database includes all the substances which have been granted an orphan designation for disease(s) considered as rare in Europe, whether they were further developed to become drugs with marketing authorisation (MA) or not.

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.

The Dutch Orphan Disease Registry Consortium has been established to build a disease registry framework to collect information on rare diseases, encourage drug development and optimize patient care.

Bronchiolitis Obliterans (BO) is a severe progressive orphan disease of the bronchioles of the lung that leads to death from respiratory failure.

Whereas FOP is so rare that it's considered an orphan disease since the disease affects so few people its symptoms are often misdiagnosed as cancer or fibrosis, and:

On the other hand, a product which was definitely described and plausibly shown to be usable, e.g. to cure a rare or orphan disease, might be considered to have a profitable use or concrete benefit, irrespective of whether it was actually intended for the pursuit of any trade at all. Thus, although no particular economic profit might be expected in the development of such products, nevertheless there was no doubt that it might be considered to display immediate concrete benefits.

Perhaps I should adopt some of these orphan diseases.

Already many children have been orphaned by this disease.

Applications include orphan diseases, critical and post-operative care, ophthalmology, or oncology.

It makes it possible to treat not only those major genetic diseases such as cystic fibrosis and myopathy, but also certain rare diseases, the so-called orphan diseases.

If, however, the desire is to treat and cure serious illnesses that are rapidly becoming more widespread, particularly cancer; to deal much better too with rare, orphan diseases, as they are termed; to confront the needs arising from the ageing of our societies’ populations; to provide better psychological and human support to patients; and to be better at developing all public research, including research into surplus embryonic stem cells, which raises new hopes, particularly in connection with illnesses linked to ageing; then, yes, if the desire is to attain all these objectives, more budgetary resources are needed.

One of the most significant developments in terms of public health is the introduction of the European policy for encouraging medicines for rare diseases (‘ orphan medicinal products’).

Further simulations suggest that funds specializing in some drug classes, such as therapies for orphan diseases, could achieve double-digit rates of return with just $250-500 million dollars and fewer compounds in the portfolio.

Moreover, biomedical research firms are abandoning certain diseases in order to avoid the large-scale trials that they require, focusing instead on “orphan diseases” like cystic fibrosis, which demand smaller clinical trials that have a higher probability of success, leading to drugs that can cost more than $100,000 annually per patient.

Finding and deploying innovative solutions, clinical tests, medicines and treatments, to combat and address age-related chronic diseases (such as Alzheimer's, Parkinson's as well as cancer, diabetes, cardiovascular diseases and other chronic diseases), whilst at the same time providing public support for research on less-frequent, rare or orphan age-related diseases (that do not attract sufficient attention from private research funding);

Indeed, these 1000 designations have already led to the authorisation of around 70 orphan medicinal products for the treatment of 62 orphan diseases.

I wanted you to know that my wife and I are looking into expanding the scope of our foundation to include orphan diseases.

While the procedure for ‘designating’ drugs for orphan diseases has improved dramatically in the EU, further ground must bemade to get orphan drugs out of the laboratory and onto the market, the group for emerging biopharmaceutical enterprises (EBE)has said.

Because of the potential for large numbers of rare genetic diseases (so-called orphan diseases), genetic testing will in many cases have to be provided by specialized reference laboratories at a European level.

Orphanet is a directory of rare diseases, orphan medicines, patient organisations, professionals, expert centres, diagnostic tests, research projects, clinical trials, registries and biobanks.

This disease area primarily includes highly prevalent non-alcoholic steatohepatitis (NASH) as well as the orphan diseases primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

Both the United States and Europe encourage companies to develop therapies for rare diseases, also known as "orphan diseases", for which there are no or only unsatisfactory treatment options.